• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's Pre-Market Session

    5/8/23 9:06:43 AM ET
    $ADTX
    $ANIP
    $APM
    $BLCM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ADTX alert in real time by email

    Gainers

    • Bellicum Pharmaceuticals (NASDAQ:BLCM) stock rose 135.4% to $0.94 during Monday's pre-market session. The market value of their outstanding shares is at $8.5 million.
    • Immuron (NASDAQ:IMRN) stock increased by 62.56% to $3.04. The company's market cap stands at $17.3 million.
    • Trevena (NASDAQ:TRVN) stock moved upwards by 24.88% to $0.79. The market value of their outstanding shares is at $7.0 million.
    • SenesTech (NASDAQ:SNES) stock increased by 24.61% to $1.62. The company's market cap stands at $4.8 million.
    • ANI Pharmaceuticals (NASDAQ:ANIP) shares moved upwards by 23.91% to $48.5. The market value of their outstanding shares is at $868.9 million. The company's, Q1 earnings came out today.
    • Sight Sciences (NASDAQ:SGHT) shares increased by 10.0% to $11.0. The market value of their outstanding shares is at $532.9 million. As per the news, the Q1 earnings report came out 2 days ago.

    Losers

    • Catalent (NYSE:CTLT) shares decreased by 21.3% to $37.6 during Monday's pre-market session. The market value of their outstanding shares is at $6.7 billion.
    • Aptorum Gr (NASDAQ:APM) shares decreased by 19.63% to $4.3. The company's market cap stands at $15.3 million.
    • Journey Medical (NASDAQ:DERM) stock fell 12.26% to $1.36. The company's market cap stands at $24.3 million.
    • Vyant Bio (NASDAQ:VYNT) shares decreased by 9.84% to $0.27. The company's market cap stands at $1.6 million.
    • BioXcel Therapeutics (NASDAQ:BTAI) stock declined by 8.9% to $21.11. The company's market cap stands at $612.3 million. As per the press release, Q1 earnings came out today.
    • Aditxt (NASDAQ:ADTX) stock declined by 8.33% to $0.61. The company's market cap stands at $3.1 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ADTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADTX
    $ANIP
    $APM
    $BLCM

    CompanyDatePrice TargetRatingAnalyst
    Sight Sciences Inc.
    $SGHT
    1/5/2026$9.00Neutral → Overweight
    Piper Sandler
    Journey Medical Corporation
    $DERM
    8/25/2025$13.00Buy
    H.C. Wainwright
    Sight Sciences Inc.
    $SGHT
    8/8/2025$5.00Hold → Buy
    Lake Street
    Journey Medical Corporation
    $DERM
    7/30/2025$12.00Buy
    B. Riley Securities
    ANI Pharmaceuticals Inc.
    $ANIP
    7/10/2025$84.00Buy
    H.C. Wainwright
    ANI Pharmaceuticals Inc.
    $ANIP
    3/14/2025$80.00Buy
    Jefferies
    ANI Pharmaceuticals Inc.
    $ANIP
    3/12/2025$85.00Overweight
    Analyst
    ANI Pharmaceuticals Inc.
    $ANIP
    12/11/2024$80.00Outperform
    Leerink Partners
    More analyst ratings

    $ADTX
    $ANIP
    $APM
    $BLCM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Sight Sciences upgraded by Piper Sandler with a new price target

    Piper Sandler upgraded Sight Sciences from Neutral to Overweight and set a new price target of $9.00

    1/5/26 8:36:47 AM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    H.C. Wainwright initiated coverage on Journey Medical with a new price target

    H.C. Wainwright initiated coverage of Journey Medical with a rating of Buy and set a new price target of $13.00

    8/25/25 8:12:40 AM ET
    $DERM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sight Sciences upgraded by Lake Street with a new price target

    Lake Street upgraded Sight Sciences from Hold to Buy and set a new price target of $5.00

    8/8/25 8:25:35 AM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    $ADTX
    $ANIP
    $APM
    $BLCM
    SEC Filings

    View All

    SEC Form 10-K filed by ANI Pharmaceuticals Inc.

    10-K - ANI PHARMACEUTICALS INC (0001023024) (Filer)

    2/27/26 6:59:42 AM ET
    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ANI Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - ANI PHARMACEUTICALS INC (0001023024) (Filer)

    2/27/26 6:57:29 AM ET
    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Immuron Limited

    6-K - Immuron Ltd (0001660046) (Filer)

    2/17/26 8:00:02 AM ET
    $IMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADTX
    $ANIP
    $APM
    $BLCM
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for IGALMI issued to BIOXCEL THERAPEUTICS, INC.

    Submission status for BIOXCEL THERAPEUTICS, INC.'s drug IGALMI (ORIG-1) with active ingredient DEXMEDETOMIDINE has changed to 'Approval' on 04/05/2022. Application Category: NDA, Application Number: 215390, Application Classification: Type 3 - New Dosage Form

    4/6/22 2:18:32 PM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for HYDROCODONE BITARTRATE AND IBUPROFEN

    Submission status for ANI PHARMS INC's drug HYDROCODONE BITARTRATE AND IBUPROFEN (SUPPL-6) with active ingredient HYDROCODONE BITARTRATE; IBUPROFEN has changed to 'Approval' on 03/04/2021. Application Category: ANDA, Application Number: 077454, Application Classification: Labeling

    3/8/21 5:11:24 AM ET
    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for OXYCODONE AND ASPIRIN

    Submission status for ANI PHARMS INC's drug OXYCODONE AND ASPIRIN (SUPPL-30) with active ingredient ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE has changed to 'Approval' on 03/04/2021. Application Category: ANDA, Application Number: 040255, Application Classification: Labeling

    3/8/21 5:11:06 AM ET
    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADTX
    $ANIP
    $APM
    $BLCM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ANI Pharmaceuticals Reports Record Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Financial Guidance

    Record quarterly and full year net revenues of $247.1 million and $883.4 million, up 29.6% and 43.8% year-over-year, respectivelyTotal Rare Disease quarterly and full year net revenue of $131.3 million and $422.6 million, up 50.8% and 84.1% year-over-year, respectively Quarterly and full year Purified Cortrophin® Gel net revenues of $111.4 million and $347.8 million, up 87.6% and 75.6% year-over-year, respectivelyQuarterly and full year ILUVIEN® and YUTIQ® net revenues of $19.8 million and $74.9 million, respectively(1) Quarterly and full year GAAP net income available to common shareholders of $27.5 million and $77.2 million, respectivelyRecord quarterly and full year adjusted non-GAAP EBIT

    2/27/26 6:50:00 AM ET
    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immuron Reports HY26 Results and Strategic Reset

    Highlights (unaudited): Consistent Revenue Growth: Immuron is no longer just a "concept" company. Global H1 FY26 sales grew to AUD$4.2 million, with the U.S. market showing strong momentum (+17% YoY).Cash (AUD $10.0 million) to fund operating activities. Includes AUD $7.3 million (net) raised at an average price of A$0.0803 (IMRN USD$2.0923).Validated Platform: The "Hyper-Immune" platform is versatile. Beyond traveler's diarrhea (Travelan®), the company is moving into high-value clinical targets like C. diff (IMM-529)Partnerships: Immuron has taken a strategic decision to pursue partnerships to fund progress of Travelan® (IMM-124E) and IMM-529 clinical programs. IMM-124E: Eligible for end o

    2/25/26 6:00:00 AM ET
    $IMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ANI Pharmaceuticals to Present at Upcoming Investor Conferences

    PRINCETON, N.J., Feb. 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, along with members of the Company's executive leadership team, will present at the following investor conferences: Raymond James & Associates' 47th Annual Institutional Investors Conference on Tuesday, March 3, 2026, at 7:30am ETLeerink Partners Global Healthcare Conference on Tuesday, March 10, 2026, at 3:00pm ETBarclays 28th Annual Global Healthcare Conference on Wednesday, March 11, 2026, at 3:00pm ET The live and archived webcasts will be accessible from the Company's website at www.anipharmaceutica

    2/24/26 6:50:00 AM ET
    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADTX
    $ANIP
    $APM
    $BLCM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    HEAD OF RARE DISEASE Mutz Christopher sold $415,300 worth of shares (5,323 units at $78.02), decreasing direct ownership by 6% to 84,840 units (SEC Form 4)

    4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)

    2/23/26 5:31:50 PM ET
    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP, CHIEF HR OFFICER Davis Krista sold $296,495 worth of shares (3,814 units at $77.74), decreasing direct ownership by 7% to 49,263 units (SEC Form 4)

    4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)

    2/23/26 5:31:33 PM ET
    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Technology Officer Badawi David exercised 21,270 shares at a strike of $0.23, increasing direct ownership by 1% to 1,998,458 units (SEC Form 4)

    4 - Sight Sciences, Inc. (0001531177) (Issuer)

    2/23/26 4:28:55 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    $ADTX
    $ANIP
    $APM
    $BLCM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Glenbrook Capital Management bought $200,635 worth of shares (85,901 units at $2.34) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    2/19/26 7:57:41 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Large owner Glenbrook Capital Management bought $56,667 worth of shares (31,346 units at $1.81) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    2/13/26 5:20:17 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Large owner Glenbrook Capital Management bought $15,480 worth of shares (8,569 units at $1.81) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    2/6/26 5:40:20 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    $ADTX
    $ANIP
    $APM
    $BLCM
    Leadership Updates

    Live Leadership Updates

    View All

    SenesTech Announces CEO Transition Plan

    Board To Initiate Search For New Leadership As Current CEO Plans Retirement Dr. Jamie Bechtel Named Interim Executive Chair To Further Support Transition PHOENIX, Jan. 28, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), a pioneer in fertility control solutions for managing rodent populations, today announced that Joel Fruendt, President and Chief Executive Officer, has informed the Board of Directors of his intent to retire. The Board will commence a formal search for a successor. Mr. Fruendt will continue to serve as President and CEO until the search is completed or until June 30, 2026, whichever occurs first.

    1/28/26 4:05:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    BioXcel Therapeutics Expands Leadership Team to Prepare for Launch of IGALMI® in the At-Home Setting

    Mark Pavao to Join BioXcel Therapeutics as Interim Chief Commercial Officer Mr. Pavao Brings Deep Experience in Neuroscience Sales and Marketing to Support Potential Launch of IGALMI® in At-Home Setting as Early as Year-End 2026 BioXcel Therapeutics on Track to Submit a sNDA for IGALMI® this Month NEW HAVEN, Conn., Jan. 12, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a biopharmaceutical company built on artificial intelligence ("AI") to develop transformative medicines in neuroscience, today announced the advancement of its commercial planning for IGALMI® in the at-home setting. As part of this, Mark Pavao, a commercial planning and launch advisor with more than 3

    1/12/26 7:00:00 AM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sight Sciences Appoints Ali Bauerlein as Chief Operating Officer and Jim Rodberg as Chief Financial Officer

    MENLO PARK, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) (Sight Sciences, or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced today the appointment of Alison (Ali) Bauerlein as its Chief Operating Officer (COO) and James (Jim) Rodberg as its Chief Financial Officer (CFO), effective November 5, 2025. "We are very excited to promote both Ali and Jim into new roles at Sight Sciences as we continue to elevate our market leadership position in MIGS and begin to scale the reimbursed interventional dry eye category. We believe the many contribu

    11/6/25 4:04:00 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    $ADTX
    $ANIP
    $APM
    $BLCM
    Financials

    Live finance-specific insights

    View All

    ANI Pharmaceuticals Reports Record Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Financial Guidance

    Record quarterly and full year net revenues of $247.1 million and $883.4 million, up 29.6% and 43.8% year-over-year, respectivelyTotal Rare Disease quarterly and full year net revenue of $131.3 million and $422.6 million, up 50.8% and 84.1% year-over-year, respectively Quarterly and full year Purified Cortrophin® Gel net revenues of $111.4 million and $347.8 million, up 87.6% and 75.6% year-over-year, respectivelyQuarterly and full year ILUVIEN® and YUTIQ® net revenues of $19.8 million and $74.9 million, respectively(1) Quarterly and full year GAAP net income available to common shareholders of $27.5 million and $77.2 million, respectivelyRecord quarterly and full year adjusted non-GAAP EBIT

    2/27/26 6:50:00 AM ET
    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sight Sciences to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026

    MENLO PARK, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced it will report financial results for the fourth quarter and full year ended December 31, 2025, after the market close on Wednesday, March 4, 2026. The Company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webcast

    2/18/26 4:05:00 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026, at 8:00 a.m. ET

    PRINCETON, N.J., Feb. 13, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced that the Company will release its fourth quarter and full year 2025 financial results on Friday, February 27, 2026, prior to the market open. Nikhil Lalwani, President and Chief Executive Officer, Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, and Chris Mutz, Head of Rare Disease will host a conference call to discuss the results as follows: DateFriday, February 27, 2026Time8:00 a.m. ETToll free (U.S.)800-274-8461Conference ID5230834Webcast (live and replay) www.anipharmaceuticals.com, under the "Investors" section The live and arc

    2/13/26 6:50:00 AM ET
    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADTX
    $ANIP
    $APM
    $BLCM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Journey Medical Corporation

    SC 13G - Journey Medical Corp (0001867066) (Subject)

    11/29/24 2:00:25 PM ET
    $DERM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by SenesTech Inc.

    SC 13G/A - SenesTech, Inc. (0001680378) (Subject)

    11/14/24 7:28:08 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Amendment: SEC Form SC 13G/A filed by SenesTech Inc.

    SC 13G/A - SenesTech, Inc. (0001680378) (Subject)

    11/14/24 7:12:23 PM ET
    $SNES
    Agricultural Chemicals
    Industrials